• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by CareDx Inc.

    6/11/25 4:20:36 PM ET
    $CDNA
    Medical Specialities
    Health Care
    Get the next $CDNA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001042875
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    CAREDX, INC.
    SEC File Number
    001-36536
    Address of Issuer
    8000 Marina Boulevard, 4th Floor
    Brisbane
    CALIFORNIA
    94005
    Phone
    415-287-2300
    Name of Person for Whose Account the Securities are To Be Sold
    WILLIAM HAGSTROM
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    19391385917.745568054906/11/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common06/11/2025Stock Option ExerciseIssuerCheckbox not checked1939106/11/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    William Hagstrom
    8000 Marina Boulevard, 4th Floor
    Brisbane � CA � 94005
    Common05/28/202530000523413.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    06/11/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ William Arthur Hagstrom

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $CDNA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDNA

    DatePrice TargetRatingAnalyst
    8/26/2025Mkt Perform
    William Blair
    1/15/2025$28.00 → $24.00Underweight → Equal Weight
    Wells Fargo
    8/28/2024$28.00Underweight
    Wells Fargo
    8/19/2024$40.00Neutral → Buy
    BTIG Research
    5/13/2024Outperform → Mkt Perform
    Raymond James
    5/1/2024$15.00Hold → Buy
    Craig Hallum
    11/9/2023$10.00Equal-Weight → Overweight
    Stephens
    8/15/2023$12.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $CDNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Secretary and General Counsel Novack Jeffrey Adam sold $41,723 worth of shares (2,688 units at $15.52), decreasing direct ownership by 2% to 105,218 units (SEC Form 4)

    4 - CareDx, Inc. (0001217234) (Issuer)

    11/10/25 4:14:40 PM ET
    $CDNA
    Medical Specialities
    Health Care

    Secretary and General Counsel Novack Jeffrey Adam covered exercise/tax liability with 2,152 shares, decreasing direct ownership by 2% to 107,906 units (SEC Form 4)

    4 - CareDx, Inc. (0001217234) (Issuer)

    11/7/25 5:22:41 PM ET
    $CDNA
    Medical Specialities
    Health Care

    Secretary and General Counsel Novack Jeffrey Adam covered exercise/tax liability with 2,872 shares, decreasing direct ownership by 3% to 110,058 units (SEC Form 4)

    4 - CareDx, Inc. (0001217234) (Issuer)

    11/4/25 4:03:02 PM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CareDx to Participate in Upcoming Investor Conferences

    CareDx, Inc. (NASDAQ:CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences: Stephens Investment Conference in Nashville, TN. Fireside chat on Wednesday, November 19, 2025, at 8am CT. Piper Sandler Healthcare Conference in New York, NY. Presentation on Wednesday, December 3, 2025, at 4:30pm ET. Live and archived webcasts of the presentations will be available on the "Events and Presentations" section of the CareDx investor rela

    11/10/25 8:00:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On November 4, 2025, as an inducement material to acceptance of employment with CareDx, 49 new employees were awarded restricted stock units (RSUs) for an aggregate of 113,250 shares of common stock. Additionally, on November 4, 2025, CareDx granted to Dr. Jeffrey Teuteberg, the Company's newly appointed Chief Medical Officer, 88,180 RSUs as an inducement material to Dr. Teuteberg's acceptan

    11/7/25 4:05:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025

    CareDx Extends Leadership in Kidney Transplant Molecular Testing with Launch of Unique Tissue-Based Gene Expression Assay – HistoMap Kidney CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new data presentations featuring CareDx technologies at American Society of Nephrology (ASN) Kidney Week 2025, underscoring the power of molecular biomarkers to advance transplant care. The company also announced the launch of HistoMap™ Kidney, a tissue-based molecular test that objec

    11/6/25 8:00:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on CareDx

    William Blair initiated coverage of CareDx with a rating of Mkt Perform

    8/26/25 8:17:26 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded CareDx from Underweight to Equal Weight and set a new price target of $24.00 from $28.00 previously

    1/15/25 7:29:19 AM ET
    $CDNA
    Medical Specialities
    Health Care

    Wells Fargo initiated coverage on CareDx with a new price target

    Wells Fargo initiated coverage of CareDx with a rating of Underweight and set a new price target of $28.00

    8/28/24 7:38:28 AM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    SEC Filings

    View All

    SEC Form S-8 filed by CareDx Inc.

    S-8 - CareDx, Inc. (0001217234) (Filer)

    11/4/25 4:26:57 PM ET
    $CDNA
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by CareDx Inc.

    10-Q - CareDx, Inc. (0001217234) (Filer)

    11/4/25 4:13:11 PM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits, Regulation FD Disclosure

    8-K - CareDx, Inc. (0001217234) (Filer)

    11/4/25 4:09:22 PM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Financials

    Live finance-specific insights

    View All

    CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025

    CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the third quarter 2025 after market close on Tuesday, November 4, 2025. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx's Investor Relations website at investors.caredx.com. To participate in the live conference call via telephone, register here. Upon registering, a

    10/21/25 8:00:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx to Report Second Quarter 2025 Financial Results

    CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-274-8461 for domestic callers or 1-203-518-9814 for international callers. Please reference Conference ID: CareDx. To listen to the webcast, plea

    7/23/25 7:05:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx to Report First Quarter 2025 Financial Results

    CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-445-7795 for domestic callers or 1-785-424-1699 for international callers. Please reference Conference ID: CareDx. To listen to the webcast, please

    4/8/25 7:05:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Leadership Updates

    Live Leadership Updates

    View All

    CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer

    Renowned Transplant Clinician to Lead CareDx Global Medical Affairs CareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Jeffrey John Teuteberg, MD, as Chief Medical Officer, effective October 1, 2025. Dr. Teuteberg brings more than two decades of experience in clinical transplantation, including senior leadership roles at Stanford University and the University of Pittsburgh Medical Center. He is board certified in Heart Failure/Cardiac Transplantation

    10/27/25 7:05:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors

    CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the appointment of Suresh Gunasekaran to its Board of Directors. Suresh currently serves as President and Chief Executive Officer at UCSF Health, an internationally renowned health system for providing highly specialized and innovative care, including solid organ and bone marrow transplantation. Suresh has more than 20 years of executive leadership experience in healthcare administration and information technology, with a proven track record of driving operational

    10/22/25 4:01:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Announces Appointment of Nathan Smith as Chief Financial Officer

    CareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Nathan Smith to the role of Chief Financial Officer. Nathan will lead key financial and accounting initiatives that are a part of the Company's long-term strategic growth plan. Nathan brings more than 14 years of experience in the molecular diagnostics industry, including senior finance leadership roles at Myriad Genetics and recent CFO positions at Blackrock Neurotech and WIN Brands. "Nathan's deep f

    8/6/25 4:57:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CareDx Inc.

    SC 13G/A - CareDx, Inc. (0001217234) (Subject)

    11/14/24 5:13:57 PM ET
    $CDNA
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by CareDx Inc.

    SC 13G/A - CareDx, Inc. (0001217234) (Subject)

    11/8/24 2:34:10 PM ET
    $CDNA
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by CareDx Inc.

    SC 13G/A - CareDx, Inc. (0001217234) (Subject)

    11/5/24 6:07:26 AM ET
    $CDNA
    Medical Specialities
    Health Care